Kirkham Young Ltd.
7 Watch Oak Business Centre, Chain Lane, Battle, East Sussex TN33 0GB

+44 (0)1424 777745
+44 (0)1424 777746

Investment raised for cancer treatment company

Oxford BioTherapeutics (OBT), an oncology-treatment company headquartered in Abingdon, Oxfordshire, has received £2 million worth of investment from Calculus Capital.

It is expected that the money will be used to fund all the components for the development of immune-oncology (IO) pre-clinical pipelines, as well as numerous other research projects for new cancer treatments in preparation for clinical-stage testing.

Funds are likely to be used to grow the business’ capital to assist with the development of therapies that will employ the patients’ immune system to distinguish and engulf threatening cancer cells.

Calculus Capital’s investment director, Alexandra Lindsay said: “Oxford BioTherapeutics has an impressive team of international immune-oncology experts and is already generating revenue through its relationships with global pharmaceutical companies, including The Menarini Group and Boehringer Ingelheim.

“As well as this, the company has four new drug treatments currently in the pre-clinical stage of development. Our investment will be used to primarily move these drugs to the next stage, which is clinical trials.”

The company works in collaboration with Italy’s most prominent pharmaceutical business, The Menarini Group, to develop phase one clinical trials for patients battling acute myeloid leukaemia, and to support those with breast, bladder and non-Hodgkin’s lymphoma.

Chief executive of OBT, Dr Christian Rohlff added: “[Calculus Capital] are investors with an impressive track record of advising and mentoring growing entrepreneurial companies and have substantial experience in the life sciences arena.”

Latest Jobs